Coronary Insufficiency
Consensus Paper | Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease
10 May, 2023 | 15:51h | UTC
Review | The bidirectional association between atrial fibrillation and myocardial infarction
8 May, 2023 | 12:54h | UTCThe bidirectional association between atrial fibrillation and myocardial infarction – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
In our latest Review, @JKornej, @EmeliaBenjamin et al. explore the bidirectional association between #AtrialFibrillation and myocardial infarction: https://t.co/K3iH24e57U pic.twitter.com/sKBrhRJXf3
— Nature Reviews Cardiology (@NatRevCardiol) April 17, 2023
Cohort Study | Subclinical coronary atherosclerosis and risk for myocardial infarction
31 Mar, 2023 | 13:36h | UTCSubclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Related:
Cohort Study: Coronary Artery Calcium and Long-Term Risk of Death, Myocardial Infarction, and Stroke
USPSTF Statement: Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors
The 10-Year Prognostic Value of Zero and Minimal CAC
Guideline | Diagnosis and treatment of vasospastic angina and coronary microvascular dysfunction
23 Mar, 2023 | 12:53h | UTCJCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction – Circulation Journal (see PDF)
SR | Myocardial revascularization in patients with ischemic cardiomyopathy: for whom and how
14 Mar, 2023 | 13:46h | UTC
M-A | Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk
8 Feb, 2023 | 12:16h | UTCDual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials – European Heart Journal (link to abstract – $ for full-text)
Commentary on Twitter
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomised trials https://t.co/bIX3fAuOEU @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/WuzOckXpFX
— European Society of Cardiology Journals (@ESC_Journals) December 20, 2022
Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts
8 Feb, 2023 | 12:14h | UTCMachine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts – The Lancet (link to abstract – $ for full-text)
News Release: Digital marker for coronary artery disease built by researchers at Mount Sinai
Commentary: Machine learning used to generate a new holistic model for coronary artery disease – News Medical
Commentary from the author on Twitter (thread – click for more)
Christmas came early… my first paper of my postdoc is officially published @TheLancet!! https://t.co/pozEyRKkD0
This was a wild journey with the @DoGenetics lab to build a digital marker for heart disease using AI + electronic health records🫀🤖 Here's why:
1/🧵— Iain S. Forrest, PhD (@IainSForrest) December 21, 2022
Transfusion thresholds for acute coronary syndromes — insights from the TRICS‐III trial and meta‐analysis
3 Feb, 2023 | 13:58h | UTC
Risk and trajectory of premature ischemic CVD in women with a history of pre-eclampsia: a nationwide register-based study
30 Jan, 2023 | 01:08h | UTCRisk and trajectory of premature ischaemic cardiovascular disease in women with a history of pre-eclampsia: a nationwide register-based study – European Journal of Preventive Cardiology (free for a limited period)
News Release: Pre-eclampsia linked with four-fold higher risk of heart attack in decade after delivery – European Society of Cardiology
Commentaries:
Preeclampsia Increases Heart Attack, Stroke Risk for Up to 20 Years After Pregnancy – HCP Live
Preeclampsia in Pregnancy a Bad Sign for Women’s Future Heart Health – HealthDay
Related:
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
Cohort Study: Preeclampsia and Cardiovascular Disease
All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease
Gestational Hypertension and Future Risk of Cardiovascular Disease
2023 Guidelines on the diagnosis and management of chronic coronary syndrome
25 Jan, 2023 | 11:25h | UTC
Retrospective Study | Serial troponin-T and long-term outcomes in suspected acute coronary syndrome
24 Jan, 2023 | 14:09h | UTC
Commentary on Twitter
Serial troponin-T and long-term outcomes in suspected acute coronary syndrome https://t.co/cTm1fJTuKl#AHA22 @ehj_ed @rladeiraslopes pic.twitter.com/0p8cO8zhzi
— European Society of Cardiology Journals (@ESC_Journals) November 7, 2022
Review | Wellens syndrome: an important consideration in patients with chest pain
23 Jan, 2023 | 13:26h | UTCWellens syndrome: An important consideration in patients with chest pain – JAAPA
Commentary: Wellens Syndrome Important to Consider if Chest Pain: Key Points – American College of Cardiology
SR | Comparison of various calcium antagonists on vasospastic angina
18 Jan, 2023 | 14:16h | UTCComparison of various calcium antagonist on vasospastic angina: a systematic review – openheart
The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischemic heart disease
9 Jan, 2023 | 14:28h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Cardiovascular Imaging https://t.co/OVJxxYu71p@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #cvimaging @chiarabd @NAjmoneMarsan pic.twitter.com/sooF0bz3LN
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023
AHA Scientific Statement | Management of acute coronary syndrome in the older adult population.
13 Dec, 2022 | 14:35h | UTCNews Release: Hearts and bodies change with age, heart disease treatments may need to change, too – American Heart Association
Top Things to Know: Management of ACS in the Older Adult Population – American Heart Association
Commentaries:
The Management of ACS in Older Patients: Is Age Just a Number? – American Heart Association
RCT | Utility of coronary CT angiography for patients with suspected acute coronary syndrome.
9 Dec, 2022 | 13:22h | UTCProspective RandOmised Trial of Emergency Cardiac Computerised Tomography (PROTECCT) – Heart
Commentary on Twitter
PROTECCT Trial @Heart_BMJ shows that immediate coronary CT in ED does not reduce length of stay in patients with suspected #AcuteCoronarySyndrome that cannot be ruled in/out on first #Troponin. @TheBHF @kingscardio @KingsImaging @GSTTresearch https://t.co/ud4rxEpmKl pic.twitter.com/YmKXFWIBZd
— Cardiac Research (@UKheartresearch) October 27, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ License
Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.
23 Nov, 2022 | 14:02h | UTCNews Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health
RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.
17 Nov, 2022 | 12:30h | UTCRelated:
Commentary on Twitter
https://twitter.com/CircAHA/status/1589647384073703426
RCT | Bivalirudin is superior to heparin in patients with ST-segment elevation myocardial infarction undergoing primary PCI.
15 Nov, 2022 | 13:00h | UTCCommentaries:
BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI – TCTMD
RCT | Indobufen vs. aspirin on top of clopidogrel after coronary drug-eluting stent implantation.
11 Nov, 2022 | 14:03h | UTC
Commentary on Twitter
#OriginalResearch simpub #AHA2022 #CIRCAHA22: In this #RCT, indobufen + clopidogrel DAPT compared with aspirin + clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, mainly driven by a reduction in bleeding events without an ….https://t.co/ctk1fwhXt2 pic.twitter.com/vFPS6gvpjN
— Circulation (@CircAHA) November 6, 2022
On the natural history of coronary artery disease: a longitudinal nationwide serial angiography study.
10 Nov, 2022 | 14:03h | UTC
Study Commentary | Radial artery beats both right internal thoracic artery and vein grafting at 15 years.
9 Nov, 2022 | 12:28h | UTC(Not published yet, presented at the American Heart Association Scientific Sessions, November 6, 2022)
RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years – TCTMD
See also:
Related:
Meta-Analysis: Radial-Artery vs Saphenous-Vein Grafts in CABG
M-A | Comparative efficacy of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after PCI.
9 Nov, 2022 | 12:20h | UTC
Follow-up of the ISCHEMIA trial | Similar survival after invasive vs. conservative management of stable coronary disease.
8 Nov, 2022 | 12:32h | UTCSurvival After Invasive or Conservative Management of Stable Coronary Disease – Circulation (free for a limited period)
Original Articles:
ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease
ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease
See also:
Commentary on Twitter
#OriginalResearch simpub #AHA2022 #CIRCAHA22: From the #ISCHEMIA-EXTEND study – No difference in all-cause mortality between initial invasive vs conservative strategy but ⬇️ risk of CV mortality and ⬆️ risk of non-CV mortality w/ initial invasive strat… https://t.co/XwFS1KO02z pic.twitter.com/SG2z4D3lzY
— Circulation (@CircAHA) November 6, 2022
M-A | Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention.
1 Nov, 2022 | 12:14h | UTC
Commentary on Twitter
Interrupting DAPT after 1 month post PCI:
Meta-analysis of 4 RCTs, >25000 pts
Events between 31days and 1yr:
Less bleeding (1.1 vs 1.5%) but no difference in death (1.3 vs 1.6%), MI (1.4 vs 1.2%), ST (0.3 vs 0.2%) or stroke (0.5 vs 0.6%) https://t.co/rdNgCg032B #cardiotwitter pic.twitter.com/yLWREcDzYe— Heeraj Bulluck (@DrHBulluck) October 30, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license